Mesoscape is a project to study the molecular epidemiology of malignant mesothelioma in Europe and has a similar set-up as Lungscape, but with a more centralised approach to process the samples. A number of major cancer centres will contribute up to 1100 cases diagnosed in the last years.
Mesoscape 001 pS6
The first module of the Mesoscape project describes the prevalence of phosphorylated ribosomal protein S6 in patients with mesothelioma and the clinical outcomes according to pS6. pS6 is a marker of the PI3K pathway and its description within this module may guide the development and testing of targeted therapies. This module was activated along with the master Mesoscape protocol.
Contact
ETOP IBCSG Partners Foundation
Effingerstrasse 33
3008 Bern, Switzerland
Rosita Kammler (Translational Research Coordinator)
Tel: +41 31 511 94 28
